Drug intelligence / Profile preview

TPIV110

Development stage: Unknown
Lead developer: Marker Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

TPIV110 is a therapeutic peptide vaccine comprising class I and II HER2/neu peptides designed to elicit both CD4+ and CD8+ T-cell responses against HER2/neu-expressing tumor cells. Developed using PolyStart and TAP technology, the vaccine targets HER2/neu-positive cancers, primarily breast cancer and ductal carcinoma in situ (DCIS). It is intended to function as an immunotherapy, either alone or in combination with other agents such as trastuzumab. Initial development and preclinical studies were undertaken by Mayo Clinic, with clinical and commercial development advanced by TapImmune (now Marker Therapeutics).

Brand names: TPIV110TPIV-110TPIV 110
Other names: TPIV110TPIV-110TPIV 110

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on TPIV110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPIV110.

Explore the full profile